Skip to main content

Tweets

Phase 2 RCT of MK2 inhibitor did not show clinical efficacy at week 12 in active AS pts compared to PBO. There are still unmet needs for additional therapeutics in pts with AS that not respond to current therapies. Abst#1760 #ACR24 @RheumNow https://t.co/cXv8HYr0Xr
Adela Castro @AdelaCastro222 ( View Tweet )
1 year 5 months ago
Comparison of infection risk across b/tsDMARDs in IA in real-world study Treatment with ➡️Rituximab ➡️JAKi ➡️Anti-IL6 assoc with ⬆️⬆️ risk of severe infection compared to TNFi A reminder to consider comorbidities & infection risk in selecting b/tsDMARDs Ab1716 #ACR24 @RheumNow

Mrinalini Dey @DrMiniDey ( View Tweet )

1 year 5 months ago
RCTs are the gold standard in drug research, but rising placebo (PBO) response rates with global recruitment could distort treatment effects. Limited access to care in less affluent countries may be a factor. #ACR24 @RheumNow ABST#1746 https://t.co/fVeNcw5qwO
Jiha Lee @JihaRheum ( View Tweet )
1 year 5 months ago
SURPASS trial of bio naïve axSpA at risk of radiographic progression: 1. Presence of syndesmophytes 2. Higher CRP levels 3. Higher ASDAS 4. Higher spinal MRI BME scores Were predictors of spinal progression independent of ttnt Abst#1759 #ACR24 @RheumNow https://t.co/QC9FMPufPY
Adela Castro @AdelaCastro222 ( View Tweet )
1 year 5 months ago
How does #race & #ethnicity impact mortality in RA? Study in CDC national mortality database ➡️RA mortality differed by race & ethnicity ➡️Highest premature mortality in Native Americans Findings may be used to inform resource allocation & management Ab1747 #ACR24 @RheumNow

Mrinalini Dey @DrMiniDey ( View Tweet )

1 year 5 months ago
In this systematic review & metaanalyis by Dr. RFarhat et al, tacrolimus whole blood levels decrease in the 1st & 2nd trimesters then increase back to pre-pregnancy levels postpartum. Needs further studies to guide dose adjustment. @RheumNow #ACR24 abs1535 https://t.co/5MovzPJoFc
1 year 5 months ago
Dr. BDinneen et al reported predictors that can help screen axSpA pts w/o traditional CV RFs for carotid doppler utz: - shorter dse duration - no family hx of IHD - HLAB27+ - ⬆️ dBP, WHratio, ferritin, TC, LDL and TC:HDL ratio Small size, more data reqd @RheumNow #ACR24 abs1440 https://t.co/3pZxFmutJz
1 year 5 months ago
Andreasson et al. High intensity interval training provides greater improvements in exercise capacity than standard moderate intensity training in IIM. @RheumNow #ACR24 Abstr#1735 https://t.co/baj7Cq2QjO https://t.co/yiE1vuk2me
Richard Conway @RichardPAConway ( View Tweet )
1 year 5 months ago
A#1748 Fracture incidence in RA - RISE registry Incidence rate of MOF, hip Fx by disease activity 50% did not have CDAI available IR 12 per 1000py hip, 43 for MOF High activity worst, low/mod similar, remission is best Supports remission is better than LDA @RheumNow #ACR24 https://t.co/78FCLemfZD
Eric Dein @ericdeinmd ( View Tweet )
1 year 5 months ago
Ab1676 discussed an intervention to change patient mindsets about side-effects of #methotrexate. Watch my video for @RheumNow on this abstract here: https://t.co/NxuxQ5wYda #ACR24

Mrinalini Dey @DrMiniDey ( View Tweet )

1 year 5 months ago
Interesting comparative effectivness study, TOFA vs calcineurin inhibitors in MDA5-dermato Expansion of prior publication @NEJM that used historical controls: https://t.co/AzA8ybCqYH Encouraging data for JAKs in this disease; need proper trials #ACR24 @RheumNow Abstr#1736 https://t.co/BHVMZLu6Ip
Mike Putman @EBRheum ( View Tweet )
1 year 5 months ago
Wu et al. MDA5-DM. Propensity-score cohort study. 672 patients. Tofacitinib vs CNI. Primary outcome 1 year death or lung transplant. HR 0.70 favouring tofacitinib. @RheumNow #ACR24 Abstr#1736 https://t.co/A0aHhp1q9c https://t.co/LbutJDBllr
Richard Conway @RichardPAConway ( View Tweet )
1 year 5 months ago
×